Joste N E, Rich J D, Busam K J, Schwartz D A
Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Arch Pathol Lab Med. 1996 Feb;120(2):199-203.
Microsporidian infections are increasingly recognized as an important cause of morbidity for persons infected with the human immunodeficiency virus. Encephalitozoon (formerly Septata) intestinalis is a recently described microsporidian that causes intestinal and disseminated infections in severely immunocompromised patients with acquired immunodeficiency syndrome. Several studies suggest that albendazole is an effective therapy for E intestinalis infection. However, relapses of symptoms and reappearance of microsporidian spores in diagnostic specimens have been reported following treatment in some cases. Because these results are based on examination of feces or cytologic specimens with an inherent sampling bias, it would be ideal to have autopsy data on the complete tissue evaluation of major organ systems of patients who had antemortem E intestinalis infection treated with albendazole. This report describes an acquired immunodeficiency syndrome patient with diarrhea and wasting syndrome associated with E intestinalis infection. Treatment with albendazole produced relief of his clinical symptoms and eliminated microsporidian spores in his feces. Following his death from other causes, an autopsy was performed. Comprehensive microscopic examination of all major organs revealed no evidence of residual microsporidian infection, suggesting parasitologic cure of E intestinalis with albendazole. The postmortem finding of complete clearance of microsporidia from body tissues is significant for future albendazole treatment of patients infected with E intestinalis and provides strong support for the value of the autopsy in evaluating the therapeutic efficacy of antimicrobials in emerging infections.
微孢子虫感染日益被认为是感染人类免疫缺陷病毒者发病的一个重要原因。肠脑炎微孢子虫(以前称为肠Septata菌)是一种最近被描述的微孢子虫,可在患有获得性免疫缺陷综合征的严重免疫功能低下患者中引起肠道感染和播散性感染。多项研究表明,阿苯达唑是治疗肠脑炎微孢子虫感染的有效疗法。然而,在某些病例中,治疗后已报告症状复发以及诊断标本中再次出现微孢子虫孢子。由于这些结果是基于对粪便或细胞学标本的检查,存在固有的抽样偏差,因此若能获得关于接受阿苯达唑治疗的生前患有肠脑炎微孢子虫感染患者主要器官系统完整组织评估的尸检数据将是理想的。本报告描述了一名患有与肠脑炎微孢子虫感染相关的腹泻和消瘦综合征的获得性免疫缺陷综合征患者。阿苯达唑治疗使他的临床症状得到缓解,并清除了他粪便中的微孢子虫孢子。在他因其他原因死亡后,进行了尸检。对所有主要器官进行的全面显微镜检查未发现残留微孢子虫感染的证据,提示阿苯达唑对肠脑炎微孢子虫有寄生虫学治愈效果。尸体解剖发现身体组织中的微孢子虫被完全清除,这对于未来用阿苯达唑治疗肠脑炎微孢子虫感染患者具有重要意义,并为尸检在评估新兴感染中抗菌药物治疗效果的价值提供了有力支持。